Changes are coming in 2019 regarding compounding and the use of chemotherapy in practices

All 50 states allow unlimited administration of drugs made under CGMP from a 503B outsourcing facility. This is a great benefit as many states do not permit unlimited office administration from a traditional 503A pharmacy. States either directly permit dispensing, or are unclear and follow FDA Federal SEC. 503B. [21 U.S.C. 353b] (attached-503B stokes) in regards to dispensing in the normal course of the practice of medicine. With the recent opioid shortage and the need for basic emergency medications, 503B will be critical in meeting these needs. Additionally, purchasing from a B manufacturer that is working under FDA oversight decreases your liability.

Please also see video link:

Submitted by Stacy Milazzo